Holen Sie sich die Stockscreener-App
1.12
5.88%
-0.07
Handel nachbörslich:
1.11
-0.01
-0.89%
Schlusskurs vom Vortag:
$1.19
Offen:
$1.17
24-Stunden-Volumen:
72,789
Relative Volume:
0.27
Marktkapitalisierung:
$91.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.65M
KGV:
-3.3725
EPS:
-0.3321
Netto-Cashflow:
$-15.84M
1W Leistung:
-0.88%
1M Leistung:
-6.67%
6M Leistung:
-51.72%
1J Leistung:
-26.80%
1-Tages-Spanne:
$1.115
$1.17
1-Wochen-Bereich:
$1.08
$1.22
52-Wochen-Spanne:
$1.03
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Vergleichen Sie CRDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.12 | 91.40M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
163.03 | 73.00B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.19 | 47.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.28 | 46.48B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.10 | 18.45B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.65 | 14.00B | 612.78M | -86.37M | -62.91M | -0.87 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Atria Investments Inc Takes Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Schedules Annual General Meeting for May 2025 - TipRanks
Financial Comparison: Cardiol Therapeutics (NASDAQ:CRDL) versus Cortexyme (NASDAQ:CRTX) - Defense World
Cardiol Therapeutics to Present at TD Cowen Health Care Conference - TipRanks
Cardiol Therapeutics to present at health care conference - Proactive Investors USA
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile
Cardiol Therapeutics (TSE:CRDL) Hits New 12-Month LowWhat's Next? - MarketBeat
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 - Investing News Network
Cardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Average PT from Analysts - Defense World
Promising Potential of Cardiol Therapeutics’ CRD-38 Justifies Buy Rating Amidst Market Need for HFpEF Treatment - TipRanks
Cardiol Therapeutics Inc. - MENAFN.COM
JACC data highlights Cardiol’s potential to differentiate in HF space - Yahoo Finance
Cardiol Therapeutics reports heart failure treatment progress By Investing.com - Investing.com Nigeria
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure - Proactive financial news
Cardiol Therapeutics reports heart failure treatment progress - Investing.com India
Cardiol Therapeutics Advances Heart Failure Treatment with New Research Publication - TipRanks
Revolutionary Heart Failure Treatment Shows Promise: Top Medical Journal Validates Multiple Therapeutic Benefits - StockTitan
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts (NASDAQ:CRDL) - Seeking Alpha
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis - Newsfile
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot - Newsfile
Biogen (NASDAQ:BIIB) vs. Cardiol Therapeutics (NASDAQ:CRDL) Head to Head Contrast - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.7%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 7.7% – Time to Sell? - Defense World
Cardiol Therapeutics (OTCMKTS:CRTPF) Trading 5.3% Higher – Here’s Why - Armenian Reporter
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Up 5.3% – Time to Buy? - Defense World
Cardiol Therapeutics to present at Oppenheimer Healthcare Conference - Proactive Investors UK
Cardiol Therapeutics to Present at Healthcare Conference, Highlighting Advances in Heart Disease Therapies - TipRanks
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile
Heart Disease Breakthrough: Cardiol Therapeutics Unveils Latest Research at Major Healthcare Summit - StockTitan
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Cardiol Therapeutics (NASDAQ:CRDL) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) PT at $8.40 - MarketBeat
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era - Yahoo Finance
Brokerages Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World
Rodman & Renshaw Begins Coverage on Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock - MSN
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock By Investing.com - Investing.com Canada
Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4%What's Next? - MarketBeat
Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 3.4% – Here’s What Happened - Defense World
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):